Intonation

Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories (Intonation) form a collaboration to fight cancerous neuroendocrine tumors

Retrieved on: 
Thursday, June 22, 2023
Health, Genetics, Other Health, Other Science, General Health, Research, Science, Heart, Endocrinology, Partnership, Stanford School, Stanford University, Intonation, Neoplasm, Glomus tumor, Cancer, IMA, Multimedia, Medicine, Doctor of Philosophy, Glioblastoma, Chemistry, Innovative Medicines Initiative, Patient, Chemical engineering, Drug discovery, Marc, Khosla, Ecosystem, Sarafan, Pharmaceutical industry, Management, Symbols of North and East Syria, MD

Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.

Key Points: 
  • Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.
  • “I’m excited about this collaboration with Intonation Research Laboratories, which has the potential to speed the translation of promising research into urgently needed new treatments and therapies,” said Marc Tessier-Lavigne , president of Stanford University.
  • “We hope to greatly accelerate our drug development program and deliver transformative treatments to patients burdened with neuroendocrine tumors,” he said.
  • “The IMA continues to seek high-quality partners in our mission as an accelerator,” said Khosla, the Marc and Jennifer Lipschultz Director of the Stanford Innovative Medicines Accelerator.

Great Speech Launches Program Offering Individual and Group Therapy for Patients with Long COVID-19

Retrieved on: 
Wednesday, August 10, 2022
Infectious Diseases, Hospitals, Health, Practice Management, Managed Care, Government budget balance, Association, Travel, Anatomical pathology, Brain, COVID, Life, Patient, National Council, Speech, ASHA, American, Depression, Program, American Speech–Language–Hearing Association, Intonation, Time, Certification, Pharmaceutical industry, Medical device

Great Speech , a pioneer and leader in virtual speech therapy, announces a new program including individual and group therapy to effectively help the estimated 7.7 million to 23 million people in the U.S. suffering with long COVID conditions .

Key Points: 
  • Great Speech , a pioneer and leader in virtual speech therapy, announces a new program including individual and group therapy to effectively help the estimated 7.7 million to 23 million people in the U.S. suffering with long COVID conditions .
  • Speech and language group therapy in addition to individual therapy can help patients who are affected by long COVID to confidently return to work, handle daily life and resume an active lifestyle.
  • CCC-SLP, Founder and Clinical Director, Great Speech, says, These patients typically begin to self-isolate, can become depressed and/or lonely.
  • Strategies that may help long COVID patients include:
    Spaced Retrieval : Patients practice recall and use of relevant information over increasingly long intervals of time.